Clinical trials: Esophagogastric Junction Disorder
Advanced Gastric Cancer, Advanced Cancer of the Esophagogastric Junction
Phase I Study of Daily RAD001 in Combination With Mitomycin C in Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction
Patients with advanced gastric cancer are treated with a combination of RAD001 (everolimus) and Mitomycin C.
- Trial name
- S387 (NCT01042782)
- Testing
- RAD001 and MitomycinC
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Krankenhaus Nordwest
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00732745
- Testing
- docetaxel, oxaliplatin, vandetanib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Case Comprehensive Cancer Center
Gastric Cancer
Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
Gastric cancer remains a significant global public health problem. Although in developed countries its incidence has dramatically decreased, on a worldwide scale it is still a leading cause of cancer-related deaths.
- Trial name
- TOPGEAR (NCT01924819)
- Testing
- Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel, Preoperative chemoradiotherapy, Gastric resection
- Where
- 59 sites in Australia, Belgium and 8 more
- Volunteers
- 574 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer
This is an open-label, single-center, single-arm, dose escalation and dose expansion Phase I/IIa study designed to determine the recommended Phase 2 dose (RP2D) and the safety and tolerability profile along with preliminary signs…
- Trial name
- NCT03707028
- Testing
- Rivoceranib, Paclitaxel
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Elevar Therapeutics
Gastroesophageal Adenocarcinoma
RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial
Esophageal and gastroesophageal junction cancers are serious diseases with limited cure rates, even when patients receive chemotherapy and surgery. New ways to improve treatment are urgently needed.
- Trial name
- RESTAGE (NCT07625930)
- Testing
- FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel), Simvastatin, Durvalumab
- Where
- Canada
- Volunteers
- 184 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Carcinoma, Endometrial Adenocarcinoma
PEN-866 in Patients With Advanced Solid Malignancies
Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
- Conditions
- Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus
- Trial name
- NCT03221400
- Testing
- PEN-866 Sodium, fluorouracil, Folinic acid
- Where
- 16 sites in United States
- Volunteers
- 340 people
- Sponsor
- Tarveda Therapeutics
Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
This is a multi-center, non-randomized, 3-cohort, phase II trial, evaluating a triplet combination of docetaxel, oxaliplatin and fluorouracil for gastric cancer with peritoneal carcinomatosis and inoperable malignant bowel…
- Conditions
- Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
- Trial name
- NCT04840264
- Testing
- Docetaxel, Oxaliplatin, Fluorouracil
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Gastric Cancer
Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
The purpose of the study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with PD-1 inhibitors and chemoradiotherapy, in comparison with adjuvant chemotherapy only, in D2/R0 resected pN3 gastric or…
- Trial name
- NCT04997837
- Testing
- PD-1 inhibitor, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 433 people
- Sponsor
- Fudan University
Gastric Cancer
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
This is a prospective, single-center, randomized controlled, phase II clinical trial. The study aims to enroll 48 patients with resectable, locally advanced gastroesophageal junction adenocarcinoma who have not received any…
- Trial name
- NCT07277439
- Testing
- Radiochemoimmunotherapy, Immunomodulation
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC)
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
This study is a multicenter, open-label, phase II clinical trial evaluating the combination of SSGJ-706 with standard therapy for advanced gastrointestinal tumors.
- Conditions
- Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Oesophageal Cancer
- Trial name
- NCT07233850
- Testing
- SSGJ-706+XELOX, SSGJ-706+Bevacizumab+XELOX, SSGJ-706+AG
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study
Gastric cancer is the third leading cause of morbidity and mortality among malignant tumors in China, and less than 30% of patients can be cured by surgery.
- Trial name
- NCT06091423
- Testing
- XELOX combined with Fruquintinib and Sintilimab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Xiaofeng Chen
Stomach Cancer, Esophageal Cancer
A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer
The purpose of this study is to determine whether ramucirumab when used in conjunction with chemotherapy treatment can help participants with stomach, esophagus, and gastroesophageal cancer.
- Trial name
- NCT01246960
- Testing
- Ramucirumab, Oxaliplatin, Leucovorin
- Where
- 58 sites in United States
- Volunteers
- 168 people
- Sponsor
- Eli Lilly and Company
Metastatic Gastric Cancer, Locally Advanced Gastric Adenocarcinoma
Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial
This study is to evaluate the efficacy and safety of domestic programmed death 1（ PD-1） antibody (Camrelizumab for injection) combined with fluorouracil plus leucovorin, oxaliplatin, and albumin bound paclitaxel (Nab-POF) regimen…
- Conditions
- Metastatic Gastric Cancer, Locally Advanced Gastric Adenocarcinoma, Gastric Cancer Adenocarcinoma Metastatic
- Trial name
- NCT04510064
- Testing
- Camrelizumab plus mFLOT regimen, R0 surgery
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of Akt inhibitor MK2206 and lapatinib ditosylate when given together with trastuzumab in treating patients with locally advanced or metastatic human epidermal growth…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01705340
- Testing
- Akt inhibitor MK2206, trastuzumab, lapatinib ditosylate
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA
ARTemIS-Eso is a phase I-II, three-level, open-label trial with a dose-expansion cohort at recommended schedule in both esophageal cancer histological groups (squamous cell carcinoma and adenocarcinoma) of RCT and ImT…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Squamous Cell Carcinoma of the Esophagus
- Trial name
- ARTEMIS-Eso (NCT03307941)
- Testing
- Monalizumab, Oxaliplatin, 5-Fluorouracil
- Where
- Belgium
- Sponsor
- Jules Bordet Institute
Metastatic Colorectal Cancer, Gastric Cancer
Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer
This is an open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of vactosertib in combination with pembrolizumab in patients with metastatic or locally advanced colorectal or…
- Conditions
- Metastatic Colorectal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT03724851
- Testing
- TEW-7197
- Where
- 5 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- MedPacto, Inc.
Esophageal Cancer, Gastric Cancer
Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as paclitaxel, carboplatin, and fluorouracil, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00022139
- Testing
- carboplatin, fluorouracil, paclitaxel
- Where
- 35 sites in United States
- Volunteers
- 56 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Gastric Cancer
Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer
Gastric cancer is one of the most common malignant tumors of the digestive tract. Gastric cancer patients diagnosed for the first time in China have a higher proportion of advanced stages and a higher postoperative metastasis…
- Trial name
- NCT04354662
- Testing
- Toripalimab, Docetaxel, Fluorouracil
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Melanoma, Breast Carcinoma
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma
- Trial name
- DUET-2 (NCT03517488)
- Testing
- XmAb20717
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Xencor, Inc.
Esophageal Cancer, Gastroesophageal Junction Cancer
Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage for Esophageal or Junctional Carcinoma.
The primary objective is to evaluate the efficacy and assess the role of Porcine Fibrin Sealant (Bioseal®) in preventing cervical anastomotic leakage after esophagectomy in the patients with resectable thoracic esophageal cancer…
- Conditions
- Esophageal Cancer, Gastroesophageal Junction Cancer, Anastomotic Leak
- Trial name
- PLACE020 (NCT03529266)
- Testing
- Porcine Fibrin Sealant (PFS), Surgery
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Sun Yat-sen University